Scholarlink

Objective <p>To update the systematic review of assessment tools on chemotherapy-induced peripheral neuropathy (CIPN) for pediatric oncology patients based on the evidence available after the published review in 2020.</p> Data sources <p>Seven English-language databases (PubMed, CINAHL, PsycINFO, EMBASE, the Cochrane Central Register of Controlled Trials, Scopus and Web of Science) were searched for studies published from Nov 9, 2018, to May 20, 2024.</p> Study selection <p>Studies that contained subjects who had a cancer diagnosis and were aged under 18&#xa0;years and discussed the development of a tool to measure CIPN or assessed all test items and response categories for CIPN were included.</p> Data extraction and synthesis <p>Data were screened and extracted independently using predesigned tables. The quality of each study was assessed based on Joanna Briggs Institute’s critical appraisal tools for analytical cross-sectional studies and case control studies. The quality of identified instruments for CIPN was evaluated by the modified version of Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool.</p> Results <p>A total of 5 studies (with 633 patients) were included in the systematic review. Only one study was rated as high quality. We newly identified two patient-reported outcome measures (PROMs), one objective assessment and a pain scale, and three new studies about the previous identified CIPN assessment measures.</p> Conclusions and relevance <p>Based on the current evidence, the pediatric-modified Total Neuropathy Score (ped-mTNS) and the Total Neuropathy Score-Pediatric Vincristine (TNS-PV) are still the two most appropriate tools for healthcare professionals to use in clinical settings. Our results also addressed the gap in existing literature by showing two newly PROMs for CIPN in pediatric oncology patients with acceptable quality. The combination of physician-based assessment tools and PROMs are recommended to evaluate the patients’ CIPN-related symptoms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Assessment measures for chemotherapy-induced peripheral neuropathy among pediatric oncology patients: an updated systematic review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月29日

查看全文
  • Ting Mao,
  • Janelle Yorke,
  • Yan Shi,
  • Nanping Shen,
  • Haixia Wang,
  • Frances-Kam-Yuet Wong,
  • Katherine Ka Wai Lam,
  • Lai Ngo Tang,
  • Qi Liu,
  • Hammoda Abu-Odah,
  • Getaneh Mulualem Belay,
  • Funa Yang,
  • Li Wang,
  • Frankie Wai Tsoi Cheng,
  • Xiaoju Zhang,
  • Ka Yan Ho

摘要

Objective

To update the systematic review of assessment tools on chemotherapy-induced peripheral neuropathy (CIPN) for pediatric oncology patients based on the evidence available after the published review in 2020.

Data sources

Seven English-language databases (PubMed, CINAHL, PsycINFO, EMBASE, the Cochrane Central Register of Controlled Trials, Scopus and Web of Science) were searched for studies published from Nov 9, 2018, to May 20, 2024.

Study selection

Studies that contained subjects who had a cancer diagnosis and were aged under 18 years and discussed the development of a tool to measure CIPN or assessed all test items and response categories for CIPN were included.

Data extraction and synthesis

Data were screened and extracted independently using predesigned tables. The quality of each study was assessed based on Joanna Briggs Institute’s critical appraisal tools for analytical cross-sectional studies and case control studies. The quality of identified instruments for CIPN was evaluated by the modified version of Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool.

Results

A total of 5 studies (with 633 patients) were included in the systematic review. Only one study was rated as high quality. We newly identified two patient-reported outcome measures (PROMs), one objective assessment and a pain scale, and three new studies about the previous identified CIPN assessment measures.

Conclusions and relevance

Based on the current evidence, the pediatric-modified Total Neuropathy Score (ped-mTNS) and the Total Neuropathy Score-Pediatric Vincristine (TNS-PV) are still the two most appropriate tools for healthcare professionals to use in clinical settings. Our results also addressed the gap in existing literature by showing two newly PROMs for CIPN in pediatric oncology patients with acceptable quality. The combination of physician-based assessment tools and PROMs are recommended to evaluate the patients’ CIPN-related symptoms.